Study Groups
WWARN facilitates a number of collaborative Study Groups to undertake individual patient data meta-analyses to answer specific research questions about malaria treatments and antimalarial drug resistance. Gathering and combining data sets from multiple studies increases sample sizes, so that effects, including smaller effects, and effects on sub-populations can be identified with greater certainty. Working together and combining data from different regions and populations is improving our understanding of drug resistance and strengthening global efforts to control and eventually eliminate malaria.
Modelling the protective effect of Artesunate-Amodiaquine (AS-AQ)A pooled analysis to assess the post-treatment prophylactic effect of artesunate-amod...
show more
Characterising the population pharmacokinetic properties of ivermectin in children and adults to inform optimal dosing of ivermectin
Assessing the efficacy of a range of antimalarials used for the treatment of P. falciparum malaria in all trimesters of pregnancy in Africa ...
show more
Exploring the impact of malaria during pregnancy on infant anaemia, malaria, morbidity and growth – an individual participant meta-analysis.
The Sulphadoxine-Pyrimethamine (SP) resistance Study Group’s aim is to provide open access to, and establish maps with, the most recent data on SP res...
show more
The Piperaquine Safety Study Group’s aim is to establish the evidence-base and safety profile to inform decision-making on the use and optimal dosing ...
show more
Development of statistical methods to infer the relationship between the percentage of resistant infections, parasite clearance half-life and the prop...
show more
A meta-analysis of individual patient data (IPD) to determine the effect of antiretroviral (ARV) drug-drug interactions and HIV disease on artemether ...
show more
The overall aim of the IPTp and SP-resistance-associated mutations Study Group is to quantify how parasites with the sextuple mutant pfdhps and pfdhfr...
show more
The First Trimester Safety of ACTs Study Group’s aim is to establish the evidence-base and safety profile to inform decision-making on the use of arte...
show more
A pooled analysis of methaemoglobin as a marker of primaquine antihypnozoite activity in Plasmodium vivax malaria
Analysis of haematological response before and after antimalarial treatment. A pooled analysis to understand the normal haematological response a...
show more
This study group aims to determine the impact of malaria in the first trimester of pregnancy on the mother and infant through individual patient data ...
show more
The paediatric single low-dose (SLD) primaquine safety study group aims to describe and compare the safety of SLD primaquine for transmission blocking...
show more
Pooled analyses of the efficacy and safety of single low-dose primaquine to interrupt P. falciparum malaria transmission.Data collection has closed an...
show more
Analysis of how age impacts the effect of primaquine dose on efficacy in patients with Plasmodium vivax and Plasmodium ovale malaria
Assessment of relationship between Haemoglobin (Hb) and Haematocrit (Hct) measurements.
An analysis of pooled individual patient data to determine the effect of antiretroviral (ARV) drug-drug interactions and HIV disease on lumefantr...
show more
Determining what affects White Blood Cell (WBC) count at baseline and during acute phase of malaria infection.
Determining the optimal Artemether-lumefantrine antimalarial dosing for young children and pregnant women: A pharmacokinetic-pharmacodynamic meta...
show more
The AL Dose Impact Study Group was first established in 2011. The Study Group first met in December 2011 at the ASTMH Annual Meeting to discuss the St...
show more
Analysing PK/PD data to identify inadequate drug exposure and inform dosageA pooled lumefantrine pharmacokinetic-pharmacodynamic (PK/PD) analysis is b...
show more
Analysis of the consequences of symptomatic Plasmodium vivax infections on anaemia before and after antimalarial treatment
Analysis of risk factors of Plasmodium vivax early and late recurrence. Published in July 2018.
Role of candidate molecular markers of lumefantrine and amodiaquine resistanceThe Artesunate-Amodiaquine/Artemether Lumefantrine (AS-AQ/AL) Molecular ...
show more
Analysing PK/PD data to identify inadequate drug exposure and inform antimalarial dosageA pooled pharmacokinetic/pharmacodynamics (PK/PD) analysis of ...
show more
Effect of DP mg/kg dosing strategies on the risk of treatment failureA pooled analysis to assess the impact of weight adjusted (mg/kg) dose variations...
show more
A population pharmacokinetic/pharmacodynamic model of pyrimethamine and sulfadoxine in participants who received either sulfadoxine-pyrimethamine (SP)...
show more
A pooled analysis on the relationship between K13 molecular marker and parasite clearance data. The Study Group closed to new participants in Dec...
show more
Parasite clearance after treatment with an artemisinin monotherapy or ACTThis Study Group characterises parasite clearance stratified by location, tre...
show more
A pooled analysis of Plasmodium falciparum gametocyte carriageThe purpose of this Study Group is to assess the risk factors for treatment failure asso...
show more
Baseline information on parasitological response to ACTs in AfricaA pooled analysis to assess the baseline early parasitological response after artemi...
show more
Effect of AS-AQ mg/kg dosing strategies on the risk of treatment failureA pooled analysis to assess the impact of weight adjusted (mg/kg) dose variati...
show more
Analysing PK/PD data to identify inadequate drug exposure and inform dosageA pooled piperaquine pharmacokinetic analysed the exposure to piperaquine i...
show more
A pooled analysis that assessed the effect of various nutritional indicators in treatment outcome in children aged 6-59 months treated with artemisini...
show more